Médico, calidad, seguridad del paciente y sistemas de salud. Physician, implementing practices evidence based, healthcare systems. Learn to share with others.
1/2📘Ya está disponible la “Actualización del consenso basado en la evidencia: indicadores mínimos para la medición, evaluación y monitoreo de la gestión del riesgo de las mujeres con #CáncerDeCuelloUterino en Colombia”.
📥Consulta en: https://t.co/E5NjQqMJ2T
#SaludEnColombia
What happens when women and communities help design their own maternity care?
A systematic review of 60 studies maps cocreation/codesign across maternal health globally, from Indigenous birthing services in Australia to digital decision-support in Bangladesh.
The consistent finding: codesign works mainly by building trust and contextual fit. Not by creating new clinical interventions.
But power imbalances within design processes are a persistent, under-acknowledged problem and scaling remains hard.
The evidence for effectiveness is still limited. The case for trying harder to involve communities is not.
Read the review here: https://t.co/EG1YTxdbMi
Regulación, acceso y cobertura: claves para entender la fertilización asistida en América Latina 📊🧬
Este estudio comparativo examina las normativas vigentes en 17 países y brechas estructurales en los servicios reproductivos.
🔗 https://t.co/AxfTEcXyXh
#SaludReproductiva
This article provides a 5 step guide, with essential tools & templates, for applying the updated Consolidated Framework for Implementation Research (CFIR) to design, conduct, analyze, interpret, & disseminate research.
Read the full article: https://t.co/Xs2jY5fh8m
Last week we published a Comment in The Lancet on the health research financing emergency facing LMICs. This crisis isn't only about service delivery – it's putting national research systems at real risk, right when countries need them most.
More at: https://t.co/B6wfugIQ8t
A paradox: we have many patient engagement interventions for diagnosis, yet robust evidence remains scarce 🤔
A scoping review examined 260 interventions across the diagnostic process, of peer-reviewed & grey literature articles.
What they found:
→ Most interventions focused on treatment (47%) and history-taking (38%)
→ Few addressed referrals (3.8%) and physical exams (2.3%)
→ Only 24% were designed WITH patients
→ Just 18.5% incorporated equity considerations
→ Most lacked rigorous evaluation
The evidence base is weak: 85% were from grey literature, only 3 RCTs (all with limitations).
Tools are scattered across the diagnostic journey, but we don't know which ones actually work. Time to prioritize equity, co-design, and proper evaluation 🎯
https://t.co/w7hjQmokkR
How to approach grey literature searching for a scoping review.
Watch members of the JBI scoping review methodology group discuss this topic from their own experiences: https://t.co/eGKd3fqdzQ
#JBImethodology#EvidenceSynthesis
How do coordination gaps among health providers shape the cancer diagnostic journey for patients in Chile, Colombia, and Ecuador?
Qualitative study examines stakeholders’ perspectives across health systems and identifies barriers to timely diagnoses.
🔗 https://t.co/6zGHz9QJ2M
The JBI Manual for Evidence Implementation gives practical, step-by-step guidance for getting evidence into practice. Use this free resource for projects aiming to ensure clinical practice is informed by the best available evidence.
🔗 https://t.co/u8kJXxU2Ue
#JBImethodology
JBI’s critical appraisal checklists use study design-specific criteria appropriate to diverse types of evidence.
💡Learn more👉 https://t.co/wS3BUn3tcX
#EvidenceSynthesis#JBIMethodology
Colombia cuenta con un modelo predictivo de ERC en SISCAC 4.0 💻📊, que estima el riesgo de desarrollar la enfermedad en personas con hipertensión ❤️ o diabetes 🩸 y permite priorizar seguimiento e intervenciones de nefroprotección 🛡️.
La evidencia sigue avanzando en antibiotic stewardship: incluso en infecciones por Pseudomonas aeruginosa, una duración de 7 días de antibiótico es generalmente suficiente. Estudios recientes no muestran beneficio en mortalidad ni supervivencia al prolongar innecesariamente el tratamiento.
Importante: estos análisis excluyeron pacientes inmunocomprometidos y neutropénicos, por lo que en estos casos la decisión debe ser individualizada y basada en la evolución clínica.
Mensaje clave: menos es más cuando está sustentado en evidencia. Reducir la duración del tratamiento no solo es seguro en muchos escenarios, sino que también ayuda a disminuir toxicidad, costos y presión selectiva para resistencia antimicrobiana.
7 días deben estar en nuestra mente como punto de partida, incluso para P. aeruginosa. @josemillanonate
In a webinar with @AcademyHealth, experts shared real-world examples – from machine learning in systematic reviews to AI-enabled analysis of national health data.
So, how should AI in #HPSR be governed and applied responsibly?
Read more: https://t.co/ihByBi5bTy
The Advocacy Strategy Framework offers essential insights into how changemakers can integrate advocacy into their #implementation work.
Check it out 👉 https://t.co/Oyouun9BWA